What Septerna, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 15 | 27 |
| Total trades | 26 | 47 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 209,628 | 305,814 |
| Disposed | 1,555,428 | 1,655,115 |
| Net activity | −1,345,800 | −1,349,301 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Long Daniel D. | SVP, Drug Discovery | Sep 01 | Open-market sale · S | −3,333 | $37.83 | −$126K | 96,412 |
| Long Daniel D. | SVP, Drug Discovery | Sep 01 | Exercise / conversion · M | +3,333 | $2.76 | +$9.2K | 99,745 |
| Third Rock Ventures V, L.p. | 10% owner | Aug 12 | Open-market sale · S | +141 | $51.08 | +$7.2K | 6,068,391 |
| Third Rock Ventures V, L.p. | 10% owner | Aug 12 | Open-market sale · S | +147,059 | $50.27 | +$7.39M | 6,068,532 |
| Ra Capital MANAGEMENT, L.p. | Director | Aug 12 | Open-market sale · S | −746,500 | $42.50 | −$31.7M | 725,443 |
| Ra Capital MANAGEMENT, L.p. | Director | Aug 12 | Open-market sale · S | −746,500 | $42.50 | −$31.7M | 4,777,415 |
| Bhatt Elizabeth | President and COO | Aug 11 | Open-market sale · S | −25,000 | $44.00 | −$1.1M | 174,209 |
| Bhatt Elizabeth | President and COO | Aug 11 | Exercise / conversion · M | +6,319 | $2.76 | +$17.4K | 199,209 |
| Bhatt Elizabeth | President and COO | Aug 11 | Exercise / conversion · M | +18,681 | $6.81 | +$127K | 192,890 |
| Long Daniel D. | SVP, Drug Discovery | Aug 03 | Open-market sale · S | −2,334 | $34.68 | −$80.9K | 96,412 |
| Long Daniel D. | SVP, Drug Discovery | Aug 03 | Open-market sale · S | −1,000 | $33.98 | −$34K | 98,746 |
| Long Daniel D. | SVP, Drug Discovery | Aug 03 | Exercise / conversion · M | +1,518 | $2.76 | +$4.19K | 99,746 |
| Long Daniel D. | SVP, Drug Discovery | Aug 03 | Exercise / conversion · M | +1,816 | $2.76 | +$5.01K | 98,228 |
| Bhatt Elizabeth | President and COO | Jul 15 | Open-market sale · S | −4,000 | $33.99 | −$136K | 174,209 |
| Bhatt Elizabeth | President and COO | Jul 15 | Exercise / conversion · M | +4,000 | $6.81 | +$27.2K | 178,209 |
| Long Daniel D. | SVP, Drug Discovery | Jul 01 | Open-market sale · S | −1,233 | $34.81 | −$42.9K | 96,412 |
| Long Daniel D. | SVP, Drug Discovery | Jul 01 | Open-market sale · S | −2,100 | $34.10 | −$71.6K | 97,645 |
| Long Daniel D. | SVP, Drug Discovery | Jul 01 | Exercise / conversion · M | +3,333 | $2.76 | +$9.2K | 99,745 |
| Shaikhly Samira | Chief People Officer | Jun 29 | Open-market sale · S | −2,178 | $35.18 | −$76.6K | 793 |
| Shaikhly Samira | Chief People Officer | Jun 29 | Exercise / conversion · M | +2,178 | $6.81 | +$14.8K | 2,971 |
Loading...